2026 Glaucoma Report

Consider approaches optometrists can take in reducing contact lens dropout to improve practice profitability and patient satisfaction.

Sit down with Drs. Garlich and Schaeffer to review the importance of validated symptom questionnaires in optimizing dry eye workups.

Join Drs. Mann, Gaan, and Heaps to review examples of their successes in myopia management and how they navigate adjusting interventions when they fail.

Next up: a 60-day review period ahead of a potential PDUFA target action date assignment; could become the first FDA-approved treatment for Stargardt.

The FDA-cleared, extended-depth-of-focus lens is the first of its kind with no warning on loss of contrast sensitivity.

Phase 3 ORUNEA trial is assessing whether targeting the biological drivers of epithelial repair can improve healing in PCED.

Review how optometrists can educate patients on and integrate nutritional support into age-related macular degeneration (AMD) management.

Learn how glaucoma surgeons can integrate canal-based procedures into their practice and complement existing MIGS techniques for improved IOP control.

Join Drs. Singh and Quezada-Ruiz as they discuss advancements in treating Stargardt disease and other retinal conditions with oral gildeuretinol.

Review the state and future of the soft contact lens market and how optometrists can empower practice staff to increase contact lens sales.

Join Drs. Lang, Leung, and Dang as they discuss what it means to be a KOL and how to engage with industry with clinical integrity.

Sit down with Dr. De Rojas as he discusses the current and future impact of artificial intelligence (AI) in ophthalmology and how he uses AI in his practice.